Pressmeddelanden
Omnio is preparing for taking the company to the next phase of development with newly appointed board
Omnio AB, a private biopharmaceutical company developing recombinant plasminogen for chronic non-healing wounds, announces the inauguration of a new board of directors that bring...
Omnio raises 1.5M EUR in successful series A funding.
Omnio AB, a private biopharmaceutical company developing recombinant plasminogen to heal chronic wounds announces a successful 1.5M EUR funding round. The funds will be allocated...
Omnio and its collaborators receives a 4.95 MSEK grant from VINNOVA, Sweden's innovation agency, for the project "Development of a new biological treatment for diabetic foot ulcers".
Vinnova has granted Omnio and its partners 4.95 million SEK to develop a safe, scalable and cost-effective biological drug and to conduct the preclinical development that will al...
Omnio AB raises 5.5MSEK in fundraising round
SWEDEN, 6th December, 2021 - Omnio AB is developing new drug products based on the pro-inflammatory and immune regulatory effects of the serum protein plasminogen. During fall th...
Omnio AB receives patent for use of inhibitors of plasminogen for treating, reducing or preventing radiation-induced injuries
Omnio receives patent approval for use of tranexamic acid (TXA) to treat, reduce and prevent radiation induced injuries. TXA is a synthetic reversible competitive inhibitor to th...
Research group at Umeå University publishes paper on the regulation of wound healing by the plasminogen receptor, Plg-RKT
The authors show that Plg-RKT is a new regulator participating in different phases of cutaneous burn wound healing, which coordinately plays a role in the interrelated responses...
Finansiell kalender
Om Omnio
Webbplats
www.omnio.se
Prenumerera
Få löpande information från Omnio via e-post.
Handelsinformation
Marknad
Onoterat